Ossium Health

02/23/2026

For more than two decades, the U.S. Government has made purposeful investments to develop medical countermeasures that can diagnose, mitigate, and treat injuries in the event of a radiological or nuclear emergency. These programs rely on strong public-private partnerships, and we’re proud to be part of this effort to ensure the nation is prepared should the unthinkable occur.

Recognizing that bone marrow is among the most sensitive and essential systems affected by radiation exposure, the Government made key investments in therapies that address myeloablation of the bone marrow following exposure to high doses of irradiation.

These critical medical countermeasures, including Ossium’s bone marrow bank, are described in a recently published review article:

“Innovative sourcing and cryopreservation of bone marrow from deceased organ donors (alternative hematopoietic progenitor cells (HPC) grafts) by Ossium Health has been explored as a means of obtaining large quantities of banked HPCs for use in myeloablated patients. These cell populations have been well-characterized, and their functionality has been found to be equivalent to live bone marrow donations.” (DiCarlo et al., 2025)

Read the full article: https://pmc.ncbi.nlm.nih.gov/articles/PMC12313093/

02/21/2026

Advances in cellular therapy are creating new possibilities for patients with blood cancers and expanding access to bone marrow transplantation beyond traditional donor sources. Franciscan Health is at the forefront of this progress, offering innovative transplant approaches, including the use of bone marrow recovered from deceased organ donors. This on-demand graft source helps reduce delays, expand donor availability, and ensure more patients have timely access to potentially lifesaving transplants.

Learn more ⬇️

10/15/2025

A recent editorial in the American Society of Clinical Oncology Journal of Clinical Oncology highlights an urgent truth for blood cancer patients: how quickly a bone marrow transplant can be performed is as critical as HLA matching.

Referencing results from the BMT CTN 1702 study, author Alessandro Rambaldi, MD emphasizes that for high-risk blood cancers like acute leukemia, faster access to a donor can make the difference between cure and relapse:

“When the risk of relapse is high, as in the case of acute leukemia patients, the shorter the time to transplant, the better the outcome. This seems particularly important, for urgent cases for whom a timeline of 6 weeks or less from unrelated search initiation to graft infusion should be considered ideal. Accordingly, disease biology, patient-related variables, and keeping the time to transplant as short as possible are more important than waiting for a better HLA-matched donor.”

At Ossium Health, we’re making that rapid access a reality. Our cryopreserved bone marrow banking platform ensures donors are available on demand, enabling bone marrow transplants to be performed within 72 hours of the initial donor search.

Read the full editorial in JCO:
🔗

Partial AccessEDITORIALSSeptember 30, 2025 Share on Looking for the Best Allogeneic Donor and the BMT CTN 1702 Study: Noli Tempus PerdereAuthor: Alessandro Rambaldi, MD https://orcid.org/0000-0002-3739-7502 [email protected]Authors Info & AffiliationsPublication: Journal of Clinical OncologyNewest ...

08/22/2025

We’re excited to share that our CEO, Co-Founder & President, Kevin Caldwell, was featured on the Biotech2050 Podcast with Rahul Chaturvedi.

In this episode, Kevin reflects on:
🔹 Building the first scalable bone marrow bank from organ donors
🔹 Ossium’s fully integrated approach to cell therapy
🔹 Lessons from raising $130M+ and navigating regulatory pathways
🔹 The conviction required to extend human healthspan through regenerative medicine

🎧 Listen here:

Podcast Episode · Biotech 2050 Podcast · 08/21/2025 · 36m

04/25/2025

Tomorrow at the Vitalist Bay Summit, Ossium CEO Kevin Caldwell is speaking on how Ossium's work in treating acute malignancies is paving the way to an expansion into preventative longevity medicine. Catch the talk at 2:10pm on the main stage.

04/14/2025

Happy National Donate Life Blue & Green Day!

02/19/2025

Our CEO Kevin Caldwell recently joined Ira Pastor on the Progress, Potential, And Possibilities podcast to discuss how Ossium is advancing stem cell science to improve patient outcomes and build a healthier future.

Listen to the conversation here:

Kevin Caldwell is CEO, Co-Founder & President of Ossium Health ( https://ossiumhealth.com/ ), a commercial stage bioengineering company that leverages its pr...

02/18/2025

Great feature in The Scientist on how Ossium’s bone marrow banking platform is transforming stem cell transplantation and expanding access for patients in need!

Read more:

Kevin Caldwell from Ossium Health explains how bone marrow banking enables physicians to quickly obtain high-quality stem cells to treat multiple diseases.

02/11/2025

We’re in Honolulu this week to exhibit at ! Join us at Booth 629 as we share exciting updates on how our bone marrow banking platform has already provided new options for stem cell transplant recipients through our PRESERVE I study and expanded access program.

Read more here:

Ossium Health, a clinical-stage bioengineering company with a first-of-its-kind bone marrow banking platform for processing and deploying hematopoieti

12/30/2024

Cell & Gene reached out to industry leaders, including Ossium’s CEO Kevin Caldwell, for predictions on what 2025 holds for biopharma. Watch the roundtable discussion here 👇

In this executive roundtable discussion, Bioprocess Online editor Tyler Menichiello is joined by CEO, co-founder, and president of Ossium Health, Kevin Caldwell, CSO of FibroBiologics, Hamid Khoja, Ph.D., and president and acting CEO of Triumvira Immunologics, Rob Williamson. The panelis...

12/11/2024

In this article from First Round, our CEO & Co-Founder Kevin Caldwell shares insight on how he reflects on past successes and failures to guide his decision-making.

Check it out:

Startup founders share their go-to questions for taking a pulse check on everything from product strategy to co-founder relationships to their own decision-making.

12/09/2024

We’re down in San Diego for some sunshine and the Annual Meeting! Come visit us at booth 217 to hear more about how our organ donor bone marrow is already improving the availability, quality, and reliability of stem cell transplants for blood cancer patients
https://www.businesswire.com/news/home/20241204632586/en